IDYA
Price
$35.20
Change
-$0.48 (-1.35%)
Updated
Dec 26 closing price
Capitalization
3.09B
94 days until earnings call
Intraday BUY SELL Signals
ZBIO
Price
$42.50
Change
-$0.67 (-1.55%)
Updated
Dec 26, 04:59 PM (EDT)
Capitalization
2.32B
60 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

IDYA vs ZBIO

Header iconIDYA vs ZBIO Comparison
Open Charts IDYA vs ZBIOBanner chart's image
IDEAYA Biosciences
Price$35.20
Change-$0.48 (-1.35%)
Volume$449.45K
Capitalization3.09B
Zenas Biopharma
Price$42.50
Change-$0.67 (-1.55%)
Volume$829
Capitalization2.32B
IDYA vs ZBIO Comparison Chart in %
IDYA
Daily Signal:
Gain/Loss:
ZBIO
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
IDYA vs. ZBIO commentary
Dec 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IDYA is a StrongBuy and ZBIO is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 27, 2025
Stock price -- (IDYA: $35.68 vs. ZBIO: $43.17)
Brand notoriety: IDYA and ZBIO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IDYA: 35% vs. ZBIO: 29%
Market capitalization -- IDYA: $3.13B vs. ZBIO: $2.32B
IDYA [@Biotechnology] is valued at $3.13B. ZBIO’s [@Biotechnology] market capitalization is $2.32B. The market cap for tickers in the [@Biotechnology] industry ranges from $117.47B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IDYA’s FA Score shows that 1 FA rating(s) are green whileZBIO’s FA Score has 1 green FA rating(s).

  • IDYA’s FA Score: 1 green, 4 red.
  • ZBIO’s FA Score: 1 green, 4 red.
According to our system of comparison, both IDYA and ZBIO are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IDYA’s TA Score shows that 3 TA indicator(s) are bullish while ZBIO’s TA Score has 5 bullish TA indicator(s).

  • IDYA’s TA Score: 3 bullish, 4 bearish.
  • ZBIO’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, ZBIO is a better buy in the short-term than IDYA.

Price Growth

IDYA (@Biotechnology) experienced а +5.78% price change this week, while ZBIO (@Biotechnology) price change was +20.55% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.37%. For the same industry, the average monthly price growth was +0.28%, and the average quarterly price growth was +55.43%.

Reported Earning Dates

IDYA is expected to report earnings on Mar 31, 2026.

ZBIO is expected to report earnings on Feb 25, 2026.

Industries' Descriptions

@Biotechnology (+0.37% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IDYA($3.09B) has a higher market cap than ZBIO($2.32B). ZBIO YTD gains are higher at: 427.106 vs. IDYA (36.965). ZBIO (-195.62M) and IDYA (-204.84M) have comparable annual earnings (EBITDA) . IDYA has more cash in the bank: 787M vs. ZBIO (291M). ZBIO has less debt than IDYA: ZBIO (798K) vs IDYA (27.2M). IDYA has higher revenues than ZBIO: IDYA (215M) vs ZBIO (15M).
IDYAZBIOIDYA / ZBIO
Capitalization3.09B2.32B133%
EBITDA-204.84M-195.62M105%
Gain YTD36.965427.1069%
P/E RatioN/A3.16-
Revenue215M15M1,433%
Total Cash787M291M270%
Total Debt27.2M798K3,409%
FUNDAMENTALS RATINGS
IDYA vs ZBIO: Fundamental Ratings
IDYA
ZBIO
OUTLOOK RATING
1..100
6445
VALUATION
overvalued / fair valued / undervalued
1..100
27
Undervalued
62
Fair valued
PROFIT vs RISK RATING
1..100
59100
SMR RATING
1..100
94100
PRICE GROWTH RATING
1..100
3934
P/E GROWTH RATING
1..100
10025
SEASONALITY SCORE
1..100
5014

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IDYA's Valuation (27) in the null industry is somewhat better than the same rating for ZBIO (62). This means that IDYA’s stock grew somewhat faster than ZBIO’s over the last 12 months.

IDYA's Profit vs Risk Rating (59) in the null industry is somewhat better than the same rating for ZBIO (100). This means that IDYA’s stock grew somewhat faster than ZBIO’s over the last 12 months.

IDYA's SMR Rating (94) in the null industry is in the same range as ZBIO (100). This means that IDYA’s stock grew similarly to ZBIO’s over the last 12 months.

ZBIO's Price Growth Rating (34) in the null industry is in the same range as IDYA (39). This means that ZBIO’s stock grew similarly to IDYA’s over the last 12 months.

ZBIO's P/E Growth Rating (25) in the null industry is significantly better than the same rating for IDYA (100). This means that ZBIO’s stock grew significantly faster than IDYA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IDYAZBIO
RSI
ODDS (%)
Bearish Trend 1 day ago
68%
Bearish Trend 3 days ago
75%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 3 days ago
76%
Momentum
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 3 days ago
90%
MACD
ODDS (%)
Bearish Trend 1 day ago
72%
Bullish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 3 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 3 days ago
90%
Advances
ODDS (%)
Bullish Trend 5 days ago
78%
Bullish Trend 3 days ago
90%
Declines
ODDS (%)
Bearish Trend 9 days ago
75%
Bearish Trend 9 days ago
80%
BollingerBands
ODDS (%)
N/A
Bullish Trend 3 days ago
67%
Aroon
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 3 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
IDYA
Daily Signal:
Gain/Loss:
ZBIO
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PRWAX80.300.23
+0.29%
T. Rowe Price All-Cap Opportunities Fund
SHXAX15.410.03
+0.20%
American Beacon Shapiro Equity Opps A
NDVRX15.490.03
+0.19%
MFS New Discovery Value R1
RMCFX10.880.02
+0.18%
Royce Micro-Cap Svc
MWOHX62.590.09
+0.14%
MFS Global Growth R3

IDYA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IDYA has been loosely correlated with NUVL. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if IDYA jumps, then NUVL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IDYA
1D Price
Change %
IDYA100%
-1.35%
NUVL - IDYA
59%
Loosely correlated
-1.57%
XENE - IDYA
58%
Loosely correlated
-0.38%
XNCR - IDYA
58%
Loosely correlated
-1.49%
CGON - IDYA
55%
Loosely correlated
-0.75%
IMTX - IDYA
54%
Loosely correlated
-1.45%
More

ZBIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZBIO has been loosely correlated with IDYA. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if ZBIO jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZBIO
1D Price
Change %
ZBIO100%
+0.84%
IDYA - ZBIO
50%
Loosely correlated
+0.76%
RGNX - ZBIO
47%
Loosely correlated
+0.77%
SYRE - ZBIO
47%
Loosely correlated
-0.54%
APGE - ZBIO
46%
Loosely correlated
+1.02%
KURA - ZBIO
45%
Loosely correlated
+2.50%
More